Myelosuppression is a major symptom in the acquired immunodeficiency syndrome (AIDS). Moreover zidovudine, an anti-retroviral drug used to treat AIDS patients has myelosuppressive side effects. Therefore treatment with IL-3, a multi-lineage hemopoietic growth factor may be beneficial for zidovudine-treated individuals. In this study we examined the effect of IL-3 on human immunodeficiency virus (HIV) expression. The proliferative response to rlL-3 and the effects on the replication of the monocytotropic HIV variant, HTLV-Ill Ba-L, in the absence or presence of the anti-retroviral drug zidovudine was studied in puri-H E HUMAN immunodeficiency virus (HIV), the caus-~~ ~ The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1990 by The American Society of Hematology. 0006-4971/90/7608-0015$3.00/0 fied human peripheral blood monocytes. Zidovudine concentrations sufficient for complete inhibition of HIV replication did not affect rlL-3 induced monocyte proliferation. Although rlL-3, like rGM-CSF, was able to augment HIV expression in monocytes, it did not interfere with the anti-retroviral activity of zidovudine. These data indicate that rlL-3 is a potential candidate for use in myelosupportive therapy in AIDS patients treated with anti-retroviral drugs.
T ative agent for the acquired immunodeficiency syndrome (AIDS), has been associated with a broad range of clinical disorders, including abnormalities of the hematopoietic system.' These abnormalities may be caused by an accelerated destruction of blood elements or interference with the production of blood cells in the bone marrow. The responsiveness of bone marrow cultures from AIDS patients to recombinant growth factors in vitro* was the basis for treatment of AIDS patients with rCSFs. In AIDS patients treated with GM-CSF, a qualitative and quantitative increase in mature neutrophils, eosinophils and monocytes has been noted. 3 The anti-retroviral agent used to treat HIVinfected persons, 3'-azido-2'3'dideoxythymidine (zidovudine) has frequently been associated with myelosuppre~sion.~ Other anti-retroviral agents are also myelotoxic although it has been reported that ddA and its metabolite ddI exhibit fewer side effects. ' This occurrence of myelosuppression has limited treatment with zidovudine. It has been suggested that hematopoietic growth factors be used in combination with this antiretroviral drug in AIDS patients.' Preliminary data from a clinical trial combining zidovudine and GM-CSF indicate that GM-CSF indeed can overcome the neutropenia resulting from zidovudine therapy.' Combinations of growth factors or treatment with rIL-3 (multi-CSF) may be necessary to overcome the multilineage cytopenias associated with AIDS and zidovudine treatment6.'
In this report, we studied rIL-3 as a possible candidate for use in combination with zidovudine. We investigated the influence of rIL-3 on HIV expression in freshly isolated human monocytes and the ability of this growth factor to induce proliferation of these peripheral blood monocytes in vitro. Moreover, the possible interference of rIL-3 with the anti-retroviral activity of zidovudine treatment as well as the possible inhibitory effect of zidovudine on rIL-3 induced proliferation in peripheral blood monocytes was studied.
MATERIALS AND METHODS

Preparation and culture of human peripheral blood monocytes.
Human peripheral blood monocytes (>95% pure) were isolated from healthy HIV seronegative donors by Percoll density gradient separation followed by centrifugal elutriation as described previously.8 Monocytes were cultured in endotoxin-free Iscove's modified Dulbec-CO'S medium (IMDM, GIBCO Laboratories, Grand Island, NY) supplemented with 7.5% (vol/vol) heat inactivated pooled human serum and antibiotics (penicillin, 100 IU/mL; streptomycin, 100 pg/mL) at a final concentration of lo6 cells/mL and plated in 96-well plates, 100 pL per/well (Nunc).
Recombinant human IL-3 (10 ng/ mL, Gist-brocades, Delft, the Netherlands) was produced by Bacillus licheninformis using the cDNA as described? It is a 15 kD non-glycosylated protein and has a correct N terminus. The sample was endotoxin free as was determined from the Limulus assay. One unit of IL-3 activity, as defined by the half-maximal response of the IL-3 dependent cell-line AML 193 corresponds to 1 ng/mL." Recombinant human GM-CSF (100 U/mL) was obtained from Sandoz Ag, Basel, Switzerland. Doses were recommended by suppliers. MDM were cultured in the presence of CSF during the first 5 days of culture.
All studies were performed with the monocytotropic HIV variant HTLV-111 Ba-L which was a kind gift of Dr M. Popovic (NCI, Bethesda, MD). Infection of cells was performed after 5 days of culture (dosis 5.105 cpm/mL RT activity). The cells were washed 24 hours after infection with 4 volumes of medium and further cultured under the conditions described above. The medium was changed every 5 days and tested for virus production in a p24-ag capture ELISA." In brief, inactivated culture supernatants were added to microtiter plates coated with purified human-a-HIV 1gG.I' After washing, bound p24 was detected with horseradish peroxidase-labeled monoclonal antibody to p24, followed by substrate. Twenty minutes before infection of the 
RESULTS
rIL-3 induces proliferation of purijed monocytes and enhances HIVexpression.
rIL-3 induced a moderate proliferation in purified peripheral blood monocytes (Fig 1 A) . This proliferation was consistently higher than the proliferation observed upon treatment with rGM-CSF. The combination of both CSFs showed the strongest induction of monocyte proliferation (Figs IA, 2A) . In a preliminary set of experiments performed to determine the optimal treatment modality for enhancement of HIV expression by rIL-3 in freshly isolated monocytes, it appeared that immediate addition of rIL-3 at the start of culture had optimal effect (data not shown). A 5-day culture in the presence of IO ng rlL-3/mL before inoculation showed an increase in virus production of 2 to 5 times compared to the unstimulated control (Fig 1 B) .
Pre-incubation with 100 U rGM-CSF/mL showed a similar increase in virus production. Treatment with a combination of rIL-3 and rGM-CSF showed a less than additional effect on virus production compared to treatment with one of the CSFs alone (Fig I B) .
Zidovudine inhibits HIVreplication in IL-3 treated monocytes without impairment of monocyte proliferation. Although rlL-3 was able to augment virus production in
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From 1492 SCHUITEMAKER ET AL monocytes, it did not interfere with the anti-retroviral effect of zidovudine (Fig 2B) . In the presence of 10 ng/mL rIL-3 during the first 5 days of culture, a dose of 1 rmol/L zidovudine was found to be sufficient to establish complete inhibition of virus production compared to a 10 pmol/L dose zidovudine in the untreated control. Even when rIL-3 was continuously present, it did not negatively affect the antiretroviral activity of zidovudine (data not shown). A similar potentiating effect was observed with rGM-CSF. The combination of both growth factors did not impair the activity of zidovudine. Knowing that zidovudine in vivo interferes with the outgrowth of hemopoietic precursor cells, we tested whether zidovudine, under conditions in which it completely inhibits HIV production, interferes with in vitro CSFinduced cell proliferation. However, under conditions of complete abolishment of HIV replication, rIL-3-induced monocyte replication was not affected by zidovudine treatment. This unaffected proliferation on day 14 of culture ( Fig  2A) , and the complete inhibition of virus expression by zidovudine at the same time indicate that down-regulation of virus replication by zidovudine in rIL-3 stimulated monocytes is not caused by inhibition of cell proliferation.
DISCUSSION
In this study we show that rIL-3, like rGM-CSF, is able to induce proliferation of purified peripheral blood monocytes and that it can augment HIV expression in this cell type. The anti-retroviral drug zidovudine was able to completely block HIV expression even in the presence of rGM-CSF or rIL-3.
The data on the enhancement of HIV expression by rIL-3 confirm previous findings by Koyanagi et ai." The additional presence of rGM-CSF only slightly enhanced the rIL-3induced effect. A similar phenomenon was recently described for rlL-3 and rGM-CSF-induced proliferation and was postulated to reflect the existence of both a common receptor and distinct receptors for these growth factors.14 We find that rIL-3, and to a lesser extent rGM-CSF, are able to induce proliferation in peripheral blood monocytes. However, the amount of 'H-thymidine incorporation is moderate, con-firming earlier findings that only a very small fraction of the monocytes (3% to 5%) has the potential to proliferate in response to rIL-3 or rGM-CSF.12 Zidovudine, at therapeutic concentration^,'^.'^ did not affect CSF-induced proliferation.
Even in the presence of the highest dose zidovudine, rIL-3induced proliferation by monocytes was observed.
The anti-retroviral effect of zidovudine was not negatively affected by the presence of rIL-3 in the culture medium. In rIL-3 treated cultures, complete inhibition of virus production was established by a concentration of 1 pmol/L zidovudine, a concentration 1 0-fold lower than the concentration necessary to establish the same effect in cultures without rIL-3. The concentration sufficient to completely block virus production did not affect the growth factor induced monocyte proliferation.
It was reported by Perno et all7 that GM-CSF potentiates the anti-retroviral effect of zidovudine by elevating the intracellular levels of the drug and by stimulating the phosphorylation of zidovudine to its active form. In our experiments we also found evidence for such potentiating effect by rGM-CSF, by rIL-3 and by the combination of both growth factors.
Proliferation of bone marrow cells is controlled by endogenous IL-3 produced by mature, CD28-t T cells.'* In previous studies, a selective loss of functionally and phenotypic mature T cells in early HIV infection was reported.19-*' The lack of endogenous IL-3 may contribute to the myelosuppression in HIV-infected individuals and may render them sensitive to the hematopoietic abnormalities induced by zidovudine treatment.
The enhancement of HIV replication in vitro by both rGM-CSF and rIL-3 observed by us and others13 seems to caution against treatment with these CSFs of HIV-infected individuals in the absence of anti-retroviral drugs, although adverse effects of mono-therapy with GM-CSF have not been reported.22 However, our results show that in combination with zidovudine, IL-3 is a potential candidate for the treatment of HIVor drug-induced myelosuppression in AIDS patients.
